|
Sign In to gain access to subscriptions and/or personal tools.
|
Chronobiology: influence of circadian rhythms on the therapy of severe pain
Uwe Junker1*
and
Stefan Wirz2
1 Ruhr-University Bochum
2 Cura Katholisches Krankenhaus
* To whom correspondence should be addressed. E-mail: u.junker{at}sana-klinikum-remscheid.de.
 |
Abstract |
|---|
Modern pain therapy widely follows the WHO (World Health Organization) guidelines using a three-step ladder for pain relief. This escalating step scheme includes the administration in the order nonopioids, mild opioids and strong opioids, and adjuvants at any step. Analgesics should be given by the clock rather than on demand. However, the chronobiological parameters circadian pain rhythm, circadian efficacy of analgesics, and individual circadian need for analgesics are to be considered. The results of a multitude of studies in chronobiology are not consistent. Therefore, further studies with standardized protocols are needed that allow to assign more consistent rhythms to diseases, pain causes, and analgesic efficacy of opioids. In many cases, each patient perceives pain and its intensity individually during the time of day. By administration of analgesics over a constant or continuous dosage time fluctuations in pain perception and the outcomes of many studies in chronobiology are ignored that prove the influence of biological rhythms on the pharmacokinetic and pharmacodynamic aspects of analgesics. As different types of pain show different rhythms (highest pain intensities arising at different times of the day) analgesics should be dosed flexibly. It is also very important that drug therapy can be adjusted individually to the pain rhythm of the patient as well as to the type and cause of pain. In severe pain, therapy should be particularly careful. A flexible dosage depending on pain intensity and rapid dose adjustment are essentials of a modern pain therapy. Therefore, opioids that are flexible to use are better suited to treat the individual pain of the patient than rigid modified release oral or transdermal systems.
First published on June 18, 2009 Journal of Oncology Pharmacy Practice 2009, doi:10.1177/1078155209337665

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|